Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K201 for prevention of atrial fibrillation recurrence after cardioversion
2009-017838-44Phase 2Terminated
- Sponsor
- Sequel Pharmaceuticals
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of K201 in Atrial fibrillation (AFib) (4 arms), sponsored by Sequel Pharmaceuticals. Primary endpoint: Effects of K201 over 28 days on endpoints of interest. Started Feb 2010; status: terminated.
02
Drugs
K201
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2009-017838-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017838-44.